NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that it has promoted Frank McGillin to Senior Vice President and Chief Commercial Officer. Mr. McGillin’s most recent title was Senior Vice President and GM Consumer. In the expanded role, Mr. McGillin will have primary responsibility for sales, marketing, and business development for the Company’s Quell® brand and wearable pain relief technology in both U.S. and international markets.
"At the time Frank joined NeuroMetrix, we had just obtained FDA clearance to market our Quell Wearable Pain Relief Technology™ directly to U.S. consumers. In the past two years, Frank and his team have rapidly built Quell into a new pain relief category with robust distribution through online, retail, and health care professional channels,” said Shai N. Gozani M.D., Ph.D., NeuroMetrix President and Chief Executive Officer. "This promotion recognizes Frank’s broad direction of the entire Quell effort, as well as his key role in Quell related operations. Moreover, Frank is leading our growing effort to develop strategic partnerships for the Quell brand and technology.”
Mr. McGillin has over 20 years of experience building successful, high-growth consumer brands. Prior to joining NeuroMetrix, he was at Philips Oral Healthcare and at Johnson & Johnson. At Philips he was responsible for building the oral care business of Sonicare to become the #1 brand in the nearly $1 billion dollar US power toothbrush market. During his career he has launched over 50 new products and product upgrades and managed businesses in diagnostic imaging, healthcare informatics, medical devices, dental and consumer technology. He holds an MBA degree from Fordham University and a BS degree from Northeastern University.
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161108005867/en/Business Wire
Last updated on: 08/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.